Clinical Trial Search

Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…

Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769

Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale

Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site

Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481

Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001

Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants

Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score

Primary: Number of Participants With Incorrect Duration of Use of the Medication — 97; 89 Participants

Primary: Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 — 11; 22; 0; 33 percentage of participants

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale

Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) — 0; 0 Participants

Primary: Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS) — 0 percentage of patients w allergic rxn

Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants

Primary: Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4 — 17.4; 37.0…

Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)

Primary: Skin Texture — 1.8; 0.5; 0 Score on a scale

Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale

Primary: Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment — 71.2; 80.8 percentage of participants — p=0.175

Primary: Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects — 2182; 2 Test site

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 — 20 Participants

Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001

Primary: Change in Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) — 11.0 score on a scale